Anaesthesia practice since introduction of sugammadex: has it changed patient outcome?
Not Applicable
Recruiting
- Conditions
- Residual neuromuscular blockade, its reversal and associated patient outcomeAnaesthesiology - Anaesthetics
- Registration Number
- ACTRN12612000087853
- Lead Sponsor
- Thomas Ledowski
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1600
Inclusion Criteria
Patients operated at Royal Perth Hospital and tracheally intubated with the use of a neuromuscular blocking agent. Hereby the reason for the operation (= original medical condition leading to treatment) is unimportant
Exclusion Criteria
Patients with significant multi-trauma, cardiothoracic surgery and patients who arrive in or leave theatres intubated
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of postoperative pulmonary complications within 30 days (assessed via an electronic record keeping software ,ISOFT, which allows access to patients' chest xray reports). In addition, we will investigate patients' medical records to see whether any clinical signs of adverse pulmonary outcome (e.g. coughing, increased oxygen demand) where observed postoperatively.[within 30 days post operation (data assessed post-hoc = from medical records [pelectronic/paper] after at least 30 days from surgery)]
- Secondary Outcome Measures
Name Time Method length of stay in the recovery room/the hospital (assessed via both electronic and paper medical records in which the outcome parameters are automatically recorded).[at any time during the study period, but at least 30 days after a patients operation];adverse airway events (oxygen desaturation, need for anaesthetist airway review/ventilation, respiratory arrest)[at least 30 days after surgery (via electronic/paper medical records)]